MIAN
ACAD icon

Mariner Independent Advisor Network’s Acadia Pharmaceuticals ACAD Stock Holding History

Mariner Independent Advisor Network’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-29,003
Closed -$651K – 145
2018
Q1 		$651K Buy
29,003
+2,695
+10% +$74.6K 0.04% 262
2017
Q4 		$753K Buy
+26,308
New +$841K 0.08% 208

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Mariner Independent Advisor Network's ACAD Position: Q2 2018 in Review

Mariner Independent Advisor Network sold out of Acadia Pharmaceuticals (ACAD) in Q2 2018, closing a stake of 29,003 shares — an estimated $651K sold.

Mariner Independent Advisor Network first reported a position in ACAD in Q4 2017 and held it in 2 quarters. The position peaked at $753K in Q4 2017. 187 funds tracked by Wall St. Rank hold ACAD as of Q2 2018.

  • Mariner Independent Advisor Network reported no remaining Acadia Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Mariner Independent Advisor Network sold 29,003 Acadia Pharmaceuticals shares in Q2 2018, an estimated $651K.
  • Mariner Independent Advisor Network first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Mariner Independent Advisor Network's Acadia Pharmaceuticals position peaked at $753K in Q4 2017.
  • 187 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2018.

Based on Mariner Independent Advisor Network's 13F filing for Q2 2018, filed 17 Sep 2018.